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Objective: To determine the prevalence of viral haemoparasites in prospective Nigerian
blood donors.
Methods: Ethical clearance was obtained and informed consent questionnaires were
distributed to blood donors to obtain their demographical data. A total of 186 blood
donors from LAUTECH Teaching Hospital, Osogbo were tested for hepatitis A virus
(HAV), hepatitis B virus (HBV) and hepatitis C virus (HCV) using rapid test kit and
enzyme linked immunosorbent assay.
Results: The highest prevalence of blood transmitted infections was 182 (97.85%) while
the prevalence of HIV, HAV, HBV and HCV were 6.45%, 97.85%, 14.52% and 3.23%,
respectively. Highest seroprevalence for hepatitis A, B and C occurred among low risk
occupation. There was no signiﬁcant association between all the hepatitis viruses and
demographic factors except occupation with P value of 0.002 7. Hepatitis A, B and C
seropositive blood donors on average tend to have PCV within the normal reference
range. Out of the 27 hepatitis B positive blood donors, 22 were donating blood for the
ﬁrst time while 5 were repeat donors. None of the hepatitis C seropositive donors have
been exposed to blood or any form of its products and were all donating blood for the ﬁrst
time. However, the distribution of donor type for HAV is random.
Conclusions: The prevalence of HAV, HBV, HCV and HIV among prospective donors
in Nigeria is alarming particularly HAV. These infections can be transmitted to recipients
if proper screening is not carried out, hence they should be included as a routine test for
blood donors.1. Introduction
Transfusion of blood and its product is a life saving measure
for anemic patient but transfusion-transmitted infections are the
most setback of transfusion practice. Infectious agents such as
hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C
virus (HCV), HIV and syphilis are among the utmost threats to
blood safety for transfusion recipients and proffer serious public
health challenges [1]. HAV is a member of the Hepatovirus
genus of the family Picornaviridae and is a non-enveloped sin-
gle-stranded RNA virus [2]. HAV replicates in hepatocytes and
interferes with liver function, sparking an immune response
that causes liver inﬂammation. Four of the seven genotypes ofHAV affect humans (genotypes I and III are the most
common), but only one serotype exists [3].
Infection with any of the genotypes usually results in lifelong
immunity against all strains of HAV. HAV is transmitted via the
fecal-oral route either by direct contact with an infectious person
or by ingestion of contaminated food or water. The risk of
disease increases with age [4]. The vast majority of hepatitis A
patients make a full recovery, and the case fatality rate is low.
The estimated mortality rate is 0.1% for children less than 15
years old, 0.3% for adults ages 15–39, and 2.1% for adults
ages 40 and above [5]. Several complications may occur; about
15% of patients experience prolonged jaundice and/or relapses
over several months. Some develop cholestatic hepatitis, in
which the bile duct leading from the liver to the intestine
becomes blocked.
A few suffer from fulminant (acute) liver failure that may
require a transplant or cause death. Although liver failure is
more likely to occur in patients suffering from chronic liver
disease prior to the onset of hepatitis A, it can occur in anyone
with HAV infection [5].under the CC BY-NC-ND license (http://
Table 1
Age distribution in relation to viral hepatitis (P = 0.005).
Age group Number HAV (%) HBV (%) HCV (%)
18–24 49 45 (24.90) 7 (3.76) 1 (0.54)
25–31 62 62 (33.34) 12 (6.45) 3 (1.61)
32–38 37 37 (19.89) 5 (2.69) 1 (0.54)
39–45 26 26 (13.98) 1 (0.54) 0 (0.00)
49–52 7 7 (3.76) 2 (1.08) 0 (0.00)
53–60 5 5 (2.69) 0 (0.00) 1 (0.54)
Total 186 182 (97.85) 27 (14.52) 6 (3.23)
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screened in blood banks routinely but HAV is not routinely
done. Due to their mode of transmission, it has made the pro-
vision of safe blood difﬁcult and the screening of blood abso-
lutely necessary [6]. Individuals with viral hepatitides chronic
infection have high risk of liver cirrhosis and hepatocellular
carcinoma. HBV and HCV have similar routes of transmission
namely through blood and its products, intravenous drug
abuse, unsafe injections and sexual activity [7].
Detection of hepatitis B surface antigen and antibodies to
HCV in blood bank is routinely carried out for detection of
hepatitis infection [8]. Globally, 320–350 million peoples are
chronic carriers of HBV and mortality of 1.5 million are being
recorded annually from HBV infection. In Nigeria, 12% of the
total populations are chronic carriers of HBV; Anti-HCV
antibody prevalence rate of 5.7% in Plateau, 8.4% in Lagos
and 9.2% in Osun among blood donors, pregnant women and
HIV patients, respectively has been reported [9]. Chronic
hepatitis C is a progressive disease that leads to death through
hepatocellular carcinoma and also predisposes to renal cell
carcinoma [10]. In Nigeria, HCV infection is still endemic and
the prevalence of hepatitis C and its mode of transmission
among Nigerians are unidentiﬁed, but latest studies across the
country among blood donors showed a prevalence ranging
between 0.4% and 12.3% [7]. This study aimed to determine
the prevalence of viral haemoparasites (HAV, HBV and HCV)
among Nigerian blood donors.Table 2
Social demographic factors in relation to viral hepatitis.
Factors Number HAV (%) HBV (%) HCV (%) P
Education level 0.081
Primary school 20 20 (100.00) 3 (15.00) 0 (0.00)
Sec. school 74 73 (95.50) 11 (14.86) 5 (5.41)
Diploma 41 41 (100.00) 7 (17.70) 1 (2.44)
Undergraduate 16 13 (81.25) 1 (6.25) 0 (0.00)
Graduate 35 35 (100.00) 5 (14.29) 1 (2.86)
Sex 0.734
Male 141 139 (74.77) 23 (12.37) 5 (2.69)
Female 45 43 (23.12) 4 (2.15) 1 (0.54)
Occupation 0.027
High risk 37 37 (19.89) 6 (3.23) 2 (1.08)
Low risk 146 142 (76.35) 21 (11.29) 4 (2.15)
Unemployed 3 3 (1.61) 0 (0.00) 0 (0.00)
Donor type 0.059
Family donor 153 152 (81.72) 21 (11.29) 5 (2.69)
Voluntary donor 30 27 (14.56) 5 (2.69) 1 (0.54)
Commercial donor 3 3 (1.61) 1 (0.54) 0 (0.00)
Prevalence 182 (97.85) 27 (14.52) 6 (3.22)
Table 3
Hematocrit levels in relation to viral hepatitis infection.
Sex PCV (%) HAV (%) HBV (%) HCV (%) P
Male 0.094
Within 40–54 135 (72.58) 22 (11.83) 5 (2.69)2. Materials and methods
The study was carried out at the Blood Transfusion Unit of
Department of Hematology, LAUTECH Teaching Hospital,
Osogbo, Nigeria. A total of 186 blood donors (141 males and 45
females) with age range 18–56 years were enrolled in this study.
Prospective donors were initially sorted using a structured
questionnaire on risk behaviors and were physically examined.
The study was approved by the ethical review committee of the
hospitals.
Blood donors were bled by venipuncture into EDTA bottle
and processed in Hematology and Microbiology Laboratory,
LAUTECH, Osogbo, Nigeria.
Blood donors were screened for HIV, HAV, HBV and HCV
antibodies. HIV 1/11 screening was done using Determine Kit
(Abbott Diagnostic Division, Hoofddorp, The Netherlands) and
later conﬁrmed with Unigold (Trinity Biotech, Ireland). Hepa-
titis A virus assay was done using competitive enzyme immu-
noassay (ELISA); reagent sourced from PRO Diagnostic Bio
probes Srl via Columella NO 31 20128 Milano, Italy while HBV
and anti-HCV assay were done using clinotech diagnostic test
kit (manufactured by Clinotech® Diagnostics, Canada). Both
positive and negative control sera were included.
Data were analyzed using Statistical Package for Social
Sciences software. Chi square was used to determine the effect
of sex, age, and other social demographic factors, including the
level of hemoglobin on HAV, HBV and HCV. The P value
<0.05 was considered to be signiﬁcant.Below <40 1 (1.61) 1 (0.54) 0 (0.00)
Above >54 1 (0.54) 0 (0.00) 0 (0.00)
Female 0.187
Within 36–46 42 (22.58) 3 (1.61) 1 (0.54)
Below <36 1 (0.54) 1 (0.54) 0 (0.00)
Above >46 2 (1.08) 0 (0.0) 0 (0.00)3. Results
The overall prevalence of blood transmitted infections in this
study was 182 (97.58%). The prevalence of HIV, HAV, HBVand HCV were 6.45%, 97.85%, 14.52% and 3.23%, respec-
tively. Table 1 showed age distribution in relation to viral hep-
atitis which showed signiﬁcant association (P = 0.005).
Prevalence of HAV, HBV and HCV infection in relation to
social demographical factors were shown in Table 2. Fourteen
(7.69%), 7 (25.9%) and 1 (16.7%) prospective blood donors had
HIV–HAV, HIV–HBV and HIV–HCV coinfection, respec-
tively. Coinfection of HBV and HCV was found in 2 (1.08%)
patients while 4 (2.15%) were non-reactive to any of the hepa-
titis viruses. Highest seroprevalence for hepatitis A, B and C
occurred among low risk occupation. There was no signiﬁcant
association between all the hepatitis viruses and demographic
factors except occupation with (P = 0.027).
The hematocrit level showed that hepatitis A, B or C sero-
positive blood donors on average tends to have PCV within the
normal reference range as shown in Table 3. Hematocrit level,
when compared with sex was not signiﬁcant. Out of the 27
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exposed to blood or its products; 22 were donating blood for the
ﬁrst time while 5 were repeat donors. None of the hepatitis C
seropositive donors have been exposed to blood or any form of
its products and were all donating blood for the ﬁrst time.
However, the distribution of donor type for HAV is random.
Family donors tend to be the most common type of donor
(82.26%) followed by Voluntary donor (16.13%); commercial
donors carried the lowest percentage (1.61%). HAV, HBV and
HCV seroprevalence among family donor are 81.72%, 11.29%
and 2.69%, respectively.
4. Discussion
The seroprevalence of HAV in this study was 97.85%, this is
very high compare to previous studies done by Ikobah et al. [11]
in rural part of southern Nigeria. Four of HAV negative donors
out of 186 sera tested for antibody to HAV are not rarely Osun
indigenes, three were student of University College Hospital and
the remaining one lives in Lagos State which indicate that Osun
state could have a HAV prevalence of 100%. Also, the four
negative blood donors do not react positively to any other
blood transmissible viruses which could imply that they have
been living healthy, hygienic and cautious life. Hepatitis A has
been documented by Nainan et al. [12] to have a worldwide
distribution and very high incidence in developing countries
and rural areas; with this, Osun justiﬁes this high prevalence
in that it is still a developing state with very poor
environmental sanitation and unhygienic personal hygiene
compared to other states in the south western region of Nigeria.
The major route of transmission for hepatitis A virus is
feacal-oral route and arises from ingestion of contaminated food
and water [13], hence the endemic outbreak of hepatitis A in
Osun is most likely to have resulted from the fact that water is
being supplied throughout the state from a single source (Ede)
which could have been infected with HAV. This is in
agreement with the study of Alter [14] posited that drinking
water contaminated by hepatitis A virus infected faeces is a
problem in communities with poor sewage treatment facilities
which is a major route of transmission of HAV.
The assay procedure for HAV in this study did not distin-
guish between immunoglobin M (IgM) anti-HAV and IgG anti-
HAV. IgM anti-HAV is an antibody to the capsid proteins of
HAV which is required to conﬁrm a diagnosis of acute HAV
infection and appears (5–10) d before the onset of symptoms and
can persist in the body system for only up to 6 month after
infection; while IgG appears earlier and remain detectable
throughout the person lifetime conﬁrming protection to the
disease. With this, it is difﬁcult to tell whether this tested pop-
ulation has a current ongoing infection or only an evidence of
past infection in their early childhood because HAV affects
mainly children [15]. No emerging risk factors for hepatitis A
have been pointed out as hepatitis A seroprevalence shows
neither preference for occupation nor any other risk behavior.
No varied distribution with regards to age, sex, literacy, and
donor type, existence of immunocompromising disease,
exposure to blood or blood products.
For HBV, the prevalence was estimated to be 14.45%which is
below value reported by Musa et al. [10] with a prevalence of
13.6% among family blood donors. From this study, it was
observed that males (12.37%) were more affected with viral
hepatitis B than their female counterparts (2.15%), which issimilar to report of Diwe et al. [16]. Of all the hepatitis B
positive donors, none had previously received a blood or blood
products transfusion and were mostly donating bloods for the
ﬁrst time signifying to an extent, hepatitis B is not Hospital
acquired. Seven (25.93%) of the 27 HBV positive donors had a
co-infection with HIV infection while 5 (3.14%) of the 159
HBV negative donors had HIV infection; with this, HIV can be
considered as a major immunocompromising diseases that pre-
disposes donor to viral hepatitis B infection. Presence of viral
hepatitis B does not have effect on donors' hematocrit level and the
two donors with reduced hematocrit level had a co-infection with
HIV most likely to be the underlie cause of reduced hematocrit
level. Liaw et al. [17] in their study posited that the hematocrit of
patients with HCV were signiﬁcantly higher than the
(9.9 ± 1.4) g/dL and 29.7% ± 4% of non-hepatitis B and C posi-
tive patients (P = 0.002 and P = 0.001). It was also observed that
those within the age bracket of 19–31 years are most affected with
high record of HBV prevalence, this may be due to the fact that
these age groups aremore sexually active [18]. It was also observed
that donor's with low skill occupation have the highest viral
hepatitis B prevalence; this may infer that occupational exposure
is not a predisposing factor for acquiring viral hepatitis B
infection. Considering donor's educational status, secondary
school qualiﬁed donors had the highest HBV prevalence of
5.92% and it is possible that most seropositivity in this group is
a result of recent vaccination considering the immunization
pattern in Nigeria.
The seroprevalence of viral hepatitis C was estimated to be
3.23% this is very low compared with previous ﬁndings by
Ejiofor et al. [19] who reported that hepatitis C virus infection is
increasing in Nigeria, from 4.7% to 5.0% in Ilorin, to 5.3%–
6.6% in Enugu, to 11% in Ibadan and 20% in Benin. All the
HCV positive donors were donating blood for the ﬁrst time
which implies that there is no difference in the prevalence of
HCV between repeat donors and ﬁrst time donors.
Paradoxically, HCV seropositivity was lowest in blood donors
who had received blood transfusion (33.33%) compared to
those who has never been exposed to transfusion (66.67%).
Published data for hepatitis C prevalence in Mauritania, Benin
and Ghana were 1.1, 1.4% and 2.8%, respectively [20]. With
all these existing facts, the prevalence of HCV among blood
donors in Osogbo estimated in this study is alarming. Among
those infected with HCV, 16.72% had a co-infection with
HIV, it can be concluded that immunocompromising (HIV)
infection is one of the predisposing factors of donors to viral
hepatitis C infection in Osogbo.
In conclusion, this study showed the presence of HAV, HBV,
HCV and HIV among prospective donors in Nigeria is alarming
particularly HAV. High prevalence of HAV is alarming and
therefore it should be included as a routine test for blood donors.
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